Florida is currently home to 3828 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Recruiting
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Boca Raton Regional Hospital, Boca Raton, Florida
Conditions: Prostate Cancer
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Recruiting
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
06/30/2025
Locations: GSK Investigational Site, Miami, Florida
Conditions: Pulmonary Disease, Chronic Obstructive
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Recruiting
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment p... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/30/2025
Locations: Novum Research LLC - Site Number : 8400018, Clermont, Florida
Conditions: Colitis Ulcerative
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension
Recruiting
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure (BP).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/30/2025
Locations: Jacksonville Center for Clinical Research, Jacksonville, Florida
Conditions: Hypertension
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
Recruiting
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/30/2025
Locations: Attovia Clinical Site 109, Coral Gables, Florida
Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Recruiting
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Florida Kidney Physicians, Boca Raton, Florida
Conditions: IgA Nephropathy
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
Recruiting
The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Cancer
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
Recruiting
In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive astrocytoma WHO grade IV.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/30/2025
Locations: UF Health Shands Hospital, Gainesville, Florida
Conditions: Recurrent Glioblastoma
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Recruiting
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/30/2025
Locations: Research Site, Boca Raton, Florida
Conditions: Polymyositis, Dermatomyositis
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: D&H Cancer Research Center- Site Number : 8400049, Margate, Florida
Conditions: Plasma Cell Myeloma Refractory
AcoArt Litos PCB Below-the-knee Global Trial
Recruiting
The objective of this study is to assess whether efficacy of the AcoArt Litos PCB is superior and whether safety of AcoArt Litos PCB is noninferior to the control device (FDA cleared PTA Balloon Catheter) regarding treatment of obstructions in the infrapopliteal arteries (located distal to the P3 segment of the popliteal artery and extending to the tibiotalar joint) in patients presenting with chronic limb-threatening ischemia (CLTI)(Rutherford 4-5)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Miami Vascular Center, Hialeah, Florida
Conditions: Chronic Limb-Threatening Ischemia
Avapritinib With Decitabine in Patients With SM-AHN
Recruiting
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm